The promise of Immuno-oncology: Implications for defining the value of cancer treatment
JournalJournal for ImmunoTherapy of Cancer
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractThe rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple stakeholders have been considering the question of "What makes I-O transformative?" Evaluating the distinct features and attributes of these therapies, and better characterizing how patients experience them, will inform such assessments. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of their value and seeks to address evidence gaps in existing value frameworks given the unique properties of patient outcomes with I-O therapy. The paper concludes with a "data needs catalogue" (DNC) predicated on the belief that multiple key, unique elements that are necessary to fully characterize the value of I-O therapies are not routinely or robustly measured in current clinical practice or reimbursement databases and are infrequently captured in existing research studies. A better characterization of the benefit of I-O treatment will allow a more thorough assessment of its benefits and provide a template for the design and prioritization of future clinical trials and a roadmap for healthcare insurers to optimize coverage for patients with cancers eligible for I-O therapy. Copyright 2019 The Author(s).
SponsorsDevelopment of this paper was supported by Pfizer Oncology and Merck KGaA.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065867563&doi=10.1186%2fs40425-019-0594-0&partnerID=40&md5=58f5d54bb03295285442e0327611a7f9; http://hdl.handle.net/10713/10795
- Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
- Authors: Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, Sasane R
- Issue date: 2019 Feb
- Procedures and methods of benefit assessments for medicines in Germany.
- Authors: Bekkering GE, Kleijnen J
- Issue date: 2008 Nov
- The project data sphere initiative: accelerating cancer research by sharing data.
- Authors: Green AK, Reeder-Hayes KE, Corty RW, Basch E, Milowsky MI, Dusetzina SB, Bennett AV, Wood WA
- Issue date: 2015 May
- Alternative metrics for assessing clinical benefit with immunotherapy in oncology.
- Authors: Chan E, Quinn C, Hirji I, Hillengass J, Anderson K, Oukessou A, Davis C
- Issue date: 2019
- End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
- Authors: Hoering A, Durie B, Wang H, Crowley J
- Issue date: 2017 Jun